Login
Navigate Fool.com
Will CUR beat
the market?

Neuralstem Inc.

NYSEMKT: CUR

Community Rating: 3 Stars: Appealing

3.79 0.01 (0.26%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.75
Previous Close $3.78
Daily Range $3.71 - $3.87
52-Week Range $1.07 - $4.80
Market Cap $326.8M
P/E Ratio -14.04
Dividend (Yield) $0.00 (0.0%)
Volume 627,964
Average Daily Volume 1,434,943
Current FY EPS -$0.23

How do you think CUR
will perform against the market?

Top CUR Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted February 24, 2011

Despite their precarious financial position the one year low for Neuralstem is 1.8. I'm going to try and jump in for a quick rebound on a volatile stock, but if I get caught in the dilution downdraft … More

0 Replies Reply Report this Post
 

geneticbiscuit (< 20)
Submitted May 4, 2010

Probably a bit early on this underperform call, but this recent run on news of entering Phase I trials for their stem cell treatments for ALS is a bit ridiculous.<br />With less than 5 million in the … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Biggest Biotech Clinical Wins of the Week

Find out which companies got the best clinical results for the week ending March 28, 2014.

Why Neuralstem Inc. Shares Soared

Neuralstem shares jumped after reporting another positive study involving its lead pipeline product, NSI-566, in rats. Can shares head even higher?

Why Neuralstem Inc. Shares Spiked Higher

Neuralstem soars after publishing its final phase 1 data for NSI-566. Should shareholders be cheering or jeering this news?

Healthcare Sector Slightly Higher Near Bell; Neuralstem Gains After Pricing $4-Mln Private Offering

Sector Update: Healthcare

Spot Tenbagger Discovery Potential in Biotech: Michael Berry

Cloning: A Stem Cell Revolution?

Will the creation of cloned human stem cells create a treatment revolution and a profitable investment?

This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.

FDA OKs Neuralstem Trial Treating Spinal Cord Injuries With Stem Cells

NSI-566 has already shown promise in ALS and rat models of spinal cord injuries.

BRIEF-Neuralstem jumps in premarket after FDA OK's spinal cord injury trial

See More CUR News...

Sector

Healthcare

Industry

Drugs

Neuralstem Inc. (CUR) Description

Neuralstem Inc is an biotechnology company which is engaged on developing and commercializing human neural stem cell technology in the emerging field of regenerative medicine. Website: http://www.neuralstem.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks